OKUR · OnKure Therapeutics, Inc.
$2.60
+0.12 (+4.85%)
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following completion of the 2026 Private Placement (see Note 9), management believes the Company's cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these condensed consolidated financial statements and as such substantial doubt has been alleviated.”View the 10-Q filed Aug 4, 2026
Market Cap
$105.09M
Shares
40.50M
Volume · Oct 27
320.24K
Avg daily vol (3M)
255.87K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.60
Open$2.49
Day$2.48–2.72
52W close$2.10–5.27
Avg vol 30d378K
Short int1.4M · 3.4% float · 2.6d
Short vol79%
Last earningsAug 4, 2026
DataApr 2021–Oct 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Apr 3, 2027
Est · unconfirmed
· in 22 wks
filed Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$58.70M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-47.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$166.50M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+269.2%
Year over year · more shares
Price change (1Y)
-27.3%
Trailing year
Short interest
3.4%
Latest settlement · 2.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.5 · elevated
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−28%
below
Price vs 50-day avg
−13%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
16%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
−36%
trailing
YTD return
−11%
this year
Relative strength
−41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
5 of 75 funds reported for Sep 30 · net -11.4K sh shares · +2 new
Insider flow
Distributing
Net -$1.2K over 90 days · 100% sells
Short interest
Rising
3.42% of float · ▲ +13.2% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
75 holders — near 3-yr high, broad support
Squeeze score
51
elevated · 0–100
Fundamentals
EPS growth
+71%
Y/Y
Free cash flow
$-51.9M
Balance sheet
$59.1M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
8.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 13, 2024
Combined company's cash, cash equivalents and short-term investm
· at the closing of the Merger
$120M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−28%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
16%
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
5 of 75 funds reported for Sep 30 · net -11.4K sh shares · +2 new
Insider flow
Distributing
Net -$1.2K over 90 days · 100% sells
Short interest
Rising
3.42% of float · ▲ +13.2% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
75 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $3 · 16%
Range high $5
vs 200-day avg -28%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OKUR
this stock
OnKure Therapeutics, Inc.
|
$105.09M | -10.5% | — | — | 3.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.20B | +14.9% | +46.2% | 30.2 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.15B | +5.7% | +20.8% | 20.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +605.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OKUR | +10.0% | -0.2% | -36.2% | -4.8% | -10.5% |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | +9.9% | -0.9% | -41.1% | -5.7% | -23.4% |